Conor Killmurray

Early results from the phase 2a MYLOX-1 study show a reduction of collagen fibrosis of the bone marrow in patients with myelofibrosis on the LOXL2 inhibitor GB2064.

Novel therapies for cutaneous T-cell lymphoma novel therapies for this patient population are helping to create straightforward management strategies.

While tyrosine kinase inhibitors the current standard of care for most patients with CML, investigators may need to look at new options and combinations for those with TKI resistance.

Pain is a clinical challenge for many oncology patients and clinicians, and there's a growing body of evidence showing that integrative therapies can be useful in pain management, according to Heather Greenlee, ND, PhD.

Pertuzumab plus trastuzumab and chemotherapy remains the standard of care for HER2-positive breast cancer, after the addition of atezolizumab did not benefit responses in the Impassion050 study.

In a retrospective analysis of 115 patients with relapsed/refractory multiple myeloma who progressed after therapy on a bispecific antibody, researchers found that the myeloma patients can be salvaged with sequential T-cell redirection therapy.

Results from the phase 2 SWOG S181 study show that for patients given pembrolizumab in the neoadjuvant setting had a significant EFS benefit compared with adjuvant pembrolizumab.

At the 2022 ESMO Congress, results from the final analysis of the RATIONALE-301 study showed that tislelizumab monotherapy continued to have clinically meaningful anti-tumor activity vs sorafenib in patients with unresectable hepatocellular carcinoma.

The FDA has approved durvalumab for the treatment of patients with locally advanced or metastatic biliary tract cancer.

Final overall survival in the ICARIA-MM study favored the combination of Isatuximab-irfc plus pomalidomide and low-dose dexamethasone.

A study of real-world outcomes of patient with relapsed or refractory multiple myeloma treated with isatuximab in now enrolling.

In a study, a correlation between frailty status and death at 1 year was identified in patients with diffuse large B-cell lymphoma.

According to patient-reported outcomes for those with endometrial cancer, the combination of lenvatinib plus pembrolizumab was favored over treatment of physician's choice.

In an interview with Targeted OncologyTM, Debra Patt, MD, PhD, MBA, FASCO, discusses the impact of delayed cancer screenings in potential patients and how the COVID-19 pandemic has increased existing inequities in cancer care.

Results from a phase 2 study revealed nivolumab plus ipilimumab to demonstrate promising clinical activity and manageable safety signals in previously treated patients with classical Kaposi sarcoma who had disease progression.

First-line durvalumab in combination with tremelimumab improved overall survival vs standard-of-care chemotherapy for the treatment of patients with metastatic non–small cell lung cancer.

Favorable overall survival results were shown with preoperative combination chemotherapy in patients with pancreatic cancer.

Advanced machine learning and natural language processing approaches were combined to identify patients with non-metastatic castration-resistant prostate cancer from electronic health records data.

President Biden announced his intent to appoint Mitchel Berger, MD, Carol L. Brown, MD, and Elizabeth M. Jaffe, MD, to the President’s Cancer Panel to help aid in the Biden-Harris administration's renewed Cancer Moonshot Program.

Results from a phase 2 study show poziotinib demonstrates significant antitumor activity for patients with EGFR exon 20 positive non–small cell lung cancer.

According to an analysis of 161 trials, patients and physicians should be encouraged to use phase 1 trials for meaningful therapy.

Data from the phase 3 ASTRA study show that selumetinib does not induce a complete remission in patients with differentiated thyroid cancer.

In an interview with Targeted Oncology, Roger Li, MD, discussed the use of the CG0070 in combination with pembrolizumab and nivolumab for patients with non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guerin.

Results from the phase 3 CLEAR trial showed lenvatinib plus everolimus to have a statistically significant improvement in progression-free survival and objective response rate compared with those given sunitinib.

At the 2022 ASCO Annual Meeting, utilizing matching-adjusted indirect comparison, researchers showed the survival benefit of larotrectinib in patients with TRK fusion-positive tumors.

At the 2022 ASCO Annual Meeting, results from the GEMSTONE-302 trial showed that adding sugemalimab to chemotherapy improved survival in patients with metastatic non–small cell lung cancer.

At the 2022 ASCO Annual Meeting, the primary analysis of the phase 2 PILOT study showed the durability and feasibility of lisocabtagene maraleucel as second-line therapy in certain patients with large B-cell lymphoma.

The European Society of Medical Oncology has announced the development of a new evidence-based classification framework to guide research and interpretation of data on the de-intensification of cancer treatments.

Researchers determined it feasible to distinguish between patients with advanced cancer who remain stable without and with early palliative care by utilizing the novel intervention tool Symptom screening with Targeted Early Palliative care.